MabVax Therapeutics Holdings, Inc.

Equities

MBVXQ

US55414P7024

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+10.05%	+182.21%

2020	MabVax Therapeutics Holdings, Inc. Went Out of Business	CI
2020	Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc.	CI

Mabvax Therapeutics Holdings, Inc. Announces Executive Terminations

August 30, 2017 at 01:49 am IST

On August 16, 2017 and August 21, 2017, Vice President and Chief Business Officer Paul F. Resnick, M.D. and Executive Vice President Research and Development Paul W. Maffuid, Ph.D. gave notice, respectively, of their intent to terminate their employment agreements with MabVax Therapeutics Holdings, Inc. for Good Reason as that term is defined in their employment agreements.

Latest news about MabVax Therapeutics Holdings, Inc.

MabVax Therapeutics Holdings, Inc. Went Out of Business	20/20/20	CI
Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc.	05/20/05	CI
Second Amended Liquidation Plan and Disclosure Statement Conditionally Approved for MabVax Therapeutics Holdings, Inc.	10/20/10	CI
Second Amended Combined Joint Liquidation Plan and Disclosure Statement Filed by MabVax Therapeutics Holdings, Inc.	08/20/08	CI
First Amended Combined Joint Liquidation Plan Filed by MabVax Therapeutics Holdings, Inc.	16/19/16	CI
Joint Liquidation Plan and Disclosure Statement Filed by MabVax Therapeutics Holdings, Inc.	27/19/27	CI
Second Motion for Exclusivity Period Extension Approved For MabVax Therapeutics Holdings, Inc.	06/19/06	CI
Motion for Exclusivity Period Extension Approved For MabVax Therapeutics Holdings, Inc.	29/19/29	CI
First Motion for Exclusivity Period Extension Filed by MabVax Therapeutics Holdings, Inc.	10/19/10	CI
Motion for Asset Sale Approved for MabVax Therapeutics Holdings, Inc.	26/19/26	CI
Bankruptcy Judge Changed for MabVax Therapeutics Holdings, Inc.	12/19/12	CI
BioNTech Research and Development, Inc. completed the acquisition of substantially all assets from MabVax Therapeutics Holdings, Inc..	08/19/08	CI
Motion for Asset Sale Approved for MabVax Therapeutics Holdings, Inc.	07/19/07	CI
Notice of Successful Bidder and Back-Up Bidder Filed by MabVax Therapeutics Holdings, Inc.	02/19/02	CI
Oncotelic Inc. cancelled the acquisition of MabVax Therapeutics Holdings, Inc. in a reverse merger transaction.	17/19/17	CI
Bidding Procedure Approved for MabVax Therapeutics Holdings, Inc.	08/19/08	CI
Final DIP Financing Approved for MabVax Therapeutics Holdings, Inc.	04/19/04	CI
Interim DIP Financing Approved for MabVax Therapeutics Holdings, Inc.	22/19/22	CI
Motion for Joint Administration Approved for MabVax Therapeutics Holdings, Inc.	22/19/22	CI
MabVax Therapeutics Holdings, Inc. Filed for Bankruptcy	21/19/21	CI
Motion for Joint Administration Filed by MabVax Therapeutics Holdings, Inc.	21/19/21	CI
Motion for Sale of Substantially All Assets Filed by MabVax Therapeutics Holdings, Inc.	21/19/21	CI
BioNTech Research and Development, Inc. agreed to acquire substantially all assets from MabVax Therapeutics Holdings, Inc. for $2.3 million.	21/19/21	CI
Oncotelic Inc. signed a non-binding letter of intent to acquire MabVax Therapeutics Holdings, Inc. in a reverse merger transaction.	04/19/04	CI
MabVax Therapeutics Engages Objective Capital as Advisor for Exploring Asset Sales	13/18/13	CI

Chart MabVax Therapeutics Holdings, Inc.

Duration

Period

Chart MabVax Therapeutics Holdings, Inc.

More charts

Company Profile

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MABVAX THERAPEUTICS HOLDINGS, INC.	+182.21%	213K
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.61%	21.96B
GENMAB A/S	-9.28%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs